Crohn’s Colitis Foundation Perspectives

Crohn’s Colitis Foundation Perspectives

By ReachMDMedicine
Download on the App Store

Crohn’s Colitis Foundation Perspectives episodes

  • Managing IBD Care for Diverse Patient Populations: Part 1
    Host: Lisa B. Malter, MD

    As the landscape of inflammatory bowel disease (IBD) patients is changing, it’s important for healthcare professionals to be aware of the diversity in patient populations and how to best serve them. That’s why the first component of this two-part webinar features gastroenterologist Dr. Lisa B. Malter, who discusses common myths surrounding IBD in certain populations and evidence-based treatment strategies for different patient groups. She’s also joined by Rocio and Tara, two patients living with IBD who share their experiences with IBD management and treatment.

    52 min
  • Managing IBD Care for Diverse Patient Populations: Part 2
    Host: Freddy Caldera, DO
    Guest: Stacy A Ogbeide, PSYD, ABPP, CSOWM
    Guest: Shubha Bhat, PharmD, MS, BCACP
    Guest: Lisa B. Malter, MD

    What cultural and cognitive biases might be contributing to health disparities in inflammatory bowel disease (IBD) care? And how can we address them? Find out in the second component of this two-part webinar featuring Drs. Freddy Caldera, Lisa B. Malter, Shubha Bhat, and Stacy Ogbeide. Together, they’ll discuss methods that can help facilitate open communication and strategies for overcoming health disparities in IBD care.

    51 min
  • IBD and Biosimilars: What Providers Need to Know
    Host: Ross M. Maltz, MD
    Guest: Shail M. Govani, MD, MSc
    Guest: Nana E. Bernasko, CRNP, WHNP-BC, DNP
    Guest: Shubha Bhat, PharmD, MS, BCACP

    As new therapies evolve, including biosimilars, it’s important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.

    13 min
  • IBD and Biosimilars: What Healthcare Professionals Need to Know
    Host: Ross M. Maltz, MD
    Guest: Shail M. Govani, MD, MSc
    Guest: Nana E. Bernasko, CRNP, WHNP-BC, DNP
    Guest: Shubha Bhat, PharmD, MS, BCACP

    As new therapies evolve, including biosimilars, it’s important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.

    13 min
  • Crohn’s Colitis Congress 2022: A Look at Diet Nutrition Therapies
    Host: Jennifer Caudle, DO
    Guest: Maitreyi Raman , MD, MSc, FRCPC

    Diet and nutrition is known to play a large role in the onset and treatment of IBD. So what were some of the trending sessions focusing on diet and nutrition at the 2022 Crohn’s & Colitis Congress? Join Dr. Jennifer Caudle as she speaks with Dr. Maitreyi Raman to explore the latest research advancements in diet therapies.

    8 min
  • Crohn's Colitis Congress 2022: Combating Challenges for Pediatric Patients
    Host: Jennifer Caudle, DO
    Guest: Ashish S. Patel, MD

    Treating IBD in our pediatric patients can be challenging, which is why creating a strong partnership between care teams and patients’ families is key. Fortunately, that was a central focus of the 2022 Crohn's & Colitis Congress, so to catch the latest updates and strategies for improving IBD care for pediatric patients, tune in to hear Dr. Jennifer Caudle speak with Dr. Ashish Patel.

    7 min
  • Crohn's Colitis Congress 2022: Improving Moderate Ulcerative Colitis Care
    Host: Jennifer Caudle, DO
    Guest: Alan C. Moss, MD, FACG, FEBG, AGAF, FRCPI

    When patients with moderate ulcerative colitis fail first-line therapy, it's important to know what to do next. And speaking with your patients about their risks and preferences is key. Join us as Dr. Alan Moss shares highlights from his presentation at the 2022 Crohn's & Colitis Congress on treatment considerations for patients with moderate ulcerative colitis.

    5 min
  • Exploring the DINE-CD Study the Importance of Diet for IBD Patients
    Host: Peter Buch, MD, FACG, AGAF, FACP
    Guest: Caren Heller, MD, MBA

    For patients living with IBD, paying special attention to their nutrition is paramount. So which is more effective for IBD patients with mild-to-moderate symptoms: a Mediterranean style diet or the Special Carbohydrate diet? That’s what the Diets to Induce Remission in Crohn's Disease (DINE-CD) study sought to find out, and now the results are in. Join Dr. Peter Buch as he explores the study's key findings with Dr. Caren Heller, Chief Scientific Officer at the Crohn's and Colitis Foundation.

    11 min
  • Endoscopic Histological Assessment, Correlation, Relapse in Clinically Quiescent Ulcerative Colitis
    Guest: Jordan E. Axelrad, MD, MPH

    Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)

    Mark T Osterman, Frank I Scott, Franz F Fogt, Erin D Gilroy, Susan Parrott, Joseph Galanko, Raymond Cross, Alan Moss, Hans H Herfarth, Peter D R Higgins

    Abstract

    Objective: It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse.

    Design: This multicenter prospective cohort study conducted by the Crohn's and Colitis Foundation Clinical Research Alliance included 100 adults with UC in clinical remission undergoing surveillance colonoscopy for dysplasia. Endoscopic activity was assessed using the Mayo endoscopic score (MES), ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS). Histology was assessed with the Riley index subcomponents, total Riley score, and basal plasmacytosis.

    Results: Only …

    5 min

About Crohn’s Colitis Foundation Perspectives

From the publisher's feed

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis.